Summit Securities Group LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,300 shares of the company’s stock, valued at approximately $453,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Acrospire Investment Management LLC raised its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the second quarter valued at approximately $129,000. Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and during the second quarter valued at approximately $148,000. 76.42% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) traded up $0.58 during mid-day trading on Monday, reaching $86.45. 3,777,100 shares of the company were exchanged, compared to its average volume of 3,673,659. The firm has a market cap of $95,189.66, a PE ratio of 21.14, a PEG ratio of 1.90 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a one year low of $67.22 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period last year, the business earned $0.88 EPS. sell-side analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 8th. Investors of record on Wednesday, November 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date was Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

A number of analysts have commented on LLY shares. Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Cowen reiterated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group reiterated a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $103.00 price target on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $90.25.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock valued at $53,399,536 over the last quarter. 0.20% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/11/summit-securities-group-llc-buys-new-position-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.